5C6 Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EST
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.03
Previous CloseN/A
Volume0.00
Average Volume (3M)N/A
Market Cap
€8.73M
Enterprise Value€5.52
Total Cash (Recent Filing)€4.12M
Total Debt (Recent Filing)€703.00K
Price to Earnings (P/E)―
Beta-0.42
Next Earnings
Aug 18, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding6,443,731,400
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.91
Price to Sales (P/S)0.66
P/FCF Ratio-2.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Service Revenue StreamsClearbridge operates multiple complementary revenue lines—individual screening packages, per-test diagnostics, and employer wellness contracts. This diversified service mix supports recurring contract revenue, cross-sell of follow-up services, and resilience to demand swings across segments over the medium term.
Strong Revenue Rebound In 2025A 33.9% top-line rebound demonstrates the company can restore demand and scale utilization of clinic and lab capacity. If sustained, higher volumes can improve fixed-cost absorption and provide a path toward operating leverage, making future margin recovery more attainable.
Manageable Reported LeverageReported debt levels are modest relative to equity, implying lower immediate refinancing stress and more financial flexibility. This manageable leverage gives the company room to fund operations or targeted investments without acute solvency risk, assuming cash burn can be contained.
Bears Say
Structural UnprofitabilityThe company has reported multi-year net losses with a material widening in 2025, indicating costs materially exceed gross profit. Persistent operating losses undermine retained earnings and make it harder to achieve sustainable profitability without significant cost restructuring or revenue scale-up.
Consistent Negative Operating And Free Cash FlowRepeated negative operating and free cash flow signal ongoing cash burn that increases reliance on external financing. Over months, this constrains investment, heightens refinancing and dilution risk, and limits the company’s ability to self-fund growth or shore up operations if losses persist.
Weakened Balance Sheet And Negative ROEDeclining equity and asset bases plus persistent negative returns on equity reflect value erosion and reduced capital buffers. A weakened balance sheet limits strategic flexibility, raises vulnerability to shocks, and makes future capital raises more dilutive or costly for shareholders.
Clearbridge Health Ltd. News
5C6 FAQ
What was Clearbridge Health Ltd.’s price range in the past 12 months?
Clearbridge Health Ltd. lowest stock price was €0.01 and its highest was €0.03 in the past 12 months.
What is Clearbridge Health Ltd.’s market cap?
Clearbridge Health Ltd.’s market cap is €8.73M.
When is Clearbridge Health Ltd.’s upcoming earnings report date?
Clearbridge Health Ltd.’s upcoming earnings report date is Aug 18, 2027 which is in 353 days.
How were Clearbridge Health Ltd.’s earnings last quarter?
Clearbridge Health Ltd. released its earnings results on Jul 31, 2026. The company reported €0 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Clearbridge Health Ltd. overvalued?
According to Wall Street analysts Clearbridge Health Ltd.’s price is currently Overvalued.
Does Clearbridge Health Ltd. pay dividends?
Clearbridge Health Ltd. does not currently pay dividends.
What is Clearbridge Health Ltd.’s EPS estimate?
Clearbridge Health Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clearbridge Health Ltd. have?
Clearbridge Health Ltd. has 6,443,731,400 shares outstanding.
What happened to Clearbridge Health Ltd.’s price movement after its last earnings report?
Clearbridge Health Ltd. reported an EPS of €0 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Clearbridge Health Ltd.?
Currently, no hedge funds are holding shares in DE:5C6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Clearbridge Health Ltd.
Established in 2010 and headquartered in Singapore, Clearbridge Health Limited operates as an investment holding company, delivering diverse healthcare solutions globally, including in Singapore, the Philippines, Hong Kong, and Malaysia. The firm's activities are organized into three key divisions: Strategic Investments, Healthcare Systems, and Medical Clinics/Centres. Its extensive range of services encompasses advanced imaging diagnostics, such as general X-ray, CT scans (including dental cone beam), mammography, MRI, and ultrasound. Furthermore, Clearbridge offers general wellness screenings for conditions like diabetes, high blood pressure, and elevated cholesterol, alongside vaccination programs. Specialized care includes renal treatment, clinical services, aesthetic procedures, and dental and orthodontic services. Beyond patient care, the company provides consultancy to healthcare organizations and is involved in the wholesale supply of medicinal and pharmaceutical products.
Asiamedic Limited
―
AJJ Medtech Holdings Limited
―
Alliance Healthcare Group Ltd.
―
Medinex Ltd.
―
Quantum Healthcare Ltd.
―